Oura Ring Gen 4 sensor data — not clinical measurementsN=1 case study — not validated for clinical decisionsHEV diagnosed Mar 18; interpret findings cautiously in this Day 67 post-ruxolitinib window

Weekly Tracker

2026-05-17 to 2026-05-23

Generated 2026-05-23 07:02 · Patient 1 — Weekly Tracker

GREEN

On Track

Metrics in normal range

AMBER

Watch

Borderline or declining

RED

Alert

Needs attention

IMPROVING

Normal

Week-over-week

DECLINING

Critical

Week-over-week

Doctor Summary — Week of 2026-05-17 to 2026-05-23

ATTENTION: Deep Sleep is declining at 0.9 h (-26.5% week-over-week)
ATTENTION: REM Sleep is declining at 0.8 h (-18.7% week-over-week)
Steps improved +387.8% to 7805 steps
Recovery Index improved +32.6% to 76 pts
Average HR declined +6.3% to 72.4 bpm -- monitor

Metric Details

HRV (RMSSD)

27.2ms

↓ -4.0%Last week: 28.3 ms

Lowest HR

59.4bpm

↔ +1.3%Last week: 58.7 bpm

Average HR

72.4bpm

↑ +6.3%Last week: 68.1 bpm

Sleep Duration

6.6h

↔ +2.2%Last week: 6.5 h

Deep Sleep

0.9h

↓ -26.5%Last week: 1.3 h

REM Sleep

0.8h

↓ -18.7%Last week: 1.0 h

Sleep Efficiency

83%

↓ -3.3%Last week: 86 %

Readiness Score

69pts

↓ -13.0%Last week: 80 pts

Recovery Index

76pts

↑ +32.6%Last week: 57 pts

Steps

7805steps

↑ +387.8%Last week: 1600 steps

Temp Deviation

0.32°C

↓ +122.1%Last week: 0.14 °C

Breath Rate

14.3brpm

↓ -8.4%Last week: 15.6 brpm

Ruxolitinib Progress

Day 68 on ruxolitinib (started 2026-03-16)

Metric	Pre-Rux Baseline	This Week	Change
HRV (RMSSD)	11.7 ms	27.2 ms	↑ +132.2%
Lowest HR	73.0 bpm	59.4 bpm	↓ -18.6%
Average HR	80.5 bpm	72.4 bpm	↓ -10.0%
Sleep Duration	6.0 h	6.6 h	↑ +11.0%
Deep Sleep	1.0 h	0.9 h	↓ -7.9%
REM Sleep	0.8 h	0.8 h	↓ -5.7%
Sleep Efficiency	79 %	83 %	↑ +4.8%
Readiness Score	69 pts	69 pts	↓ -0.1%
Recovery Index	63 pts	76 pts	↑ +20.1%
Steps	2540 steps	7805 steps	↑ +207.2%
Temp Deviation	0.21 °C	0.32 °C	↑ +56.5%
Breath Rate	14.0 brpm	14.3 brpm	↑ +2.4%

All metrics derived from Oura Ring Gen 4 consumer wearable data. Not clinical-grade measurements.

Single-patient case study (N=1). Not validated for clinical decision-making. Not a medical device.

Data: January 08 – May 21, 2026 · Post-intervention: 67 days (ruxolitinib, March 16)